{"pmid":32407746,"pmcid":"PMC7214308","title":"Prevalence of diabetes mellitus in 2019 novel coronavirus: a Meta-analysis.","text":["Prevalence of diabetes mellitus in 2019 novel coronavirus: a Meta-analysis.","BACKGROUND: Since December 2019, a new strain ofcoronavirus named 2019 novel coronavirus (2019-nCoV) has been discovered in Wuhan. The prevalence of diabetes mellitus, which is a great public health issue leading to immunity inhibition and anincreased incidenceofinfections, has been increasing over the past ten years. The aim of this research was to systematically assess the prevalence of diabetes mellitus among 2019-nCoV. METHODS: We searched PubMed, Embase, Web of Science and Medline for observational studies up to February 25, 2020. A random effects model or fixed-effects model was applied to evaluate the pooled prevalence of diabetes mellitus and odds ratio (OR) with 95% confidence interval (CI). FINDINGS: In total, nine papers met the eligibility criteria. The pooled prevalence of DM was 9% (95% CI 6%-12%). There was obvious heterogeneity (I(2) 65%, p=0.004) in the prevalence of DM in these studies. The prevalence of DM in moderate patients with 2019-nCoV was 7% (95% CI 4%-10%). The prevalence of DM in severe patients with 2019-nCoV was 17% (95% CI 13%-21%). The prevalence of DM in severe patients with 2019-nCoV was significantly higher than that in moderate patients with 2019-nCoV (OR 2.49, 95% CI 1.70 to 3.64). INTERPRETATION: To our knowledge, this work is the first report showing the prevalence of diabetes mellitus in patients with 2019-nCoV, which is beneficial to prevent the spread of 2019-nCoV in the future.","Diabetes Res Clin Pract","Wang, Xiang","Wang, Shoujun","Sun, Liangge","Qin, Guijun","32407746"],"abstract":["BACKGROUND: Since December 2019, a new strain ofcoronavirus named 2019 novel coronavirus (2019-nCoV) has been discovered in Wuhan. The prevalence of diabetes mellitus, which is a great public health issue leading to immunity inhibition and anincreased incidenceofinfections, has been increasing over the past ten years. The aim of this research was to systematically assess the prevalence of diabetes mellitus among 2019-nCoV. METHODS: We searched PubMed, Embase, Web of Science and Medline for observational studies up to February 25, 2020. A random effects model or fixed-effects model was applied to evaluate the pooled prevalence of diabetes mellitus and odds ratio (OR) with 95% confidence interval (CI). FINDINGS: In total, nine papers met the eligibility criteria. The pooled prevalence of DM was 9% (95% CI 6%-12%). There was obvious heterogeneity (I(2) 65%, p=0.004) in the prevalence of DM in these studies. The prevalence of DM in moderate patients with 2019-nCoV was 7% (95% CI 4%-10%). The prevalence of DM in severe patients with 2019-nCoV was 17% (95% CI 13%-21%). The prevalence of DM in severe patients with 2019-nCoV was significantly higher than that in moderate patients with 2019-nCoV (OR 2.49, 95% CI 1.70 to 3.64). INTERPRETATION: To our knowledge, this work is the first report showing the prevalence of diabetes mellitus in patients with 2019-nCoV, which is beneficial to prevent the spread of 2019-nCoV in the future."],"journal":"Diabetes Res Clin Pract","authors":["Wang, Xiang","Wang, Shoujun","Sun, Liangge","Qin, Guijun"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407746","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.diabres.2020.108200","keywords":["2019 novel coronavirus","diabetes mellitus","meta-analysis","prevalence"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666950579806535681,"score":9.490897,"similar":[{"pmid":32334395,"pmcid":"PMC7162793","title":"Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression.","text":["Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression.","BACKGROUND AND AIMS: Diabetes Mellitus (DM) is chronic conditions with devastating multi-systemic complication and may be associated with severe form of Coronavirus Disease 2019 (COVID-19). We conducted a systematic review and meta-analysis in order to investigate the association between DM and poor outcome in patients with COVID-19 pneumonia. METHODS: Systematic literature search was performed from several electronic databases on subjects that assess DM and outcome in COVID-19 pneumonia. The outcome of interest was composite poor outcome, including mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care unit (ICU) care, and disease progression. RESULTS: There were a total of 6452 patients from 30 studies. Meta-analysis showed that DM was associated with composite poor outcome (RR 2.38 [1.88, 3.03], p < 0.001; I(2): 62%) and its subgroup which comprised of mortality (RR 2.12 [1.44, 3.11], p < 0.001; I(2): 72%), severe COVID-19 (RR 2.45 [1.79, 3.35], p < 0.001; I(2): 45%), ARDS (RR 4.64 [1.86, 11.58], p = 0.001; I(2): 9%), and disease progression (RR 3.31 [1.08, 10.14], p = 0.04; I(2): 0%). Meta-regression showed that the association with composite poor outcome was influenced by age (p = 0.003) and hypertension (p < 0.001). Subgroup analysis showed that the association was weaker in studies with median age >/=55 years-old (RR 1.92) compared to <55 years-old (RR 3.48), and in prevalence of hypertension >/=25% (RR 1.93) compared to <25% (RR 3.06). Subgroup analysis on median age <55 years-old and prevalence of hypertension <25% showed strong association (RR 3.33) CONCLUSION: DM was associated with mortality, severe COVID-19, ARDS, and disease progression in patients with COVID-19.","Diabetes Metab Syndr","Huang, Ian","Lim, Michael Anthonius","Pranata, Raymond","32334395"],"abstract":["BACKGROUND AND AIMS: Diabetes Mellitus (DM) is chronic conditions with devastating multi-systemic complication and may be associated with severe form of Coronavirus Disease 2019 (COVID-19). We conducted a systematic review and meta-analysis in order to investigate the association between DM and poor outcome in patients with COVID-19 pneumonia. METHODS: Systematic literature search was performed from several electronic databases on subjects that assess DM and outcome in COVID-19 pneumonia. The outcome of interest was composite poor outcome, including mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care unit (ICU) care, and disease progression. RESULTS: There were a total of 6452 patients from 30 studies. Meta-analysis showed that DM was associated with composite poor outcome (RR 2.38 [1.88, 3.03], p < 0.001; I(2): 62%) and its subgroup which comprised of mortality (RR 2.12 [1.44, 3.11], p < 0.001; I(2): 72%), severe COVID-19 (RR 2.45 [1.79, 3.35], p < 0.001; I(2): 45%), ARDS (RR 4.64 [1.86, 11.58], p = 0.001; I(2): 9%), and disease progression (RR 3.31 [1.08, 10.14], p = 0.04; I(2): 0%). Meta-regression showed that the association with composite poor outcome was influenced by age (p = 0.003) and hypertension (p < 0.001). Subgroup analysis showed that the association was weaker in studies with median age >/=55 years-old (RR 1.92) compared to <55 years-old (RR 3.48), and in prevalence of hypertension >/=25% (RR 1.93) compared to <25% (RR 3.06). Subgroup analysis on median age <55 years-old and prevalence of hypertension <25% showed strong association (RR 3.33) CONCLUSION: DM was associated with mortality, severe COVID-19, ARDS, and disease progression in patients with COVID-19."],"journal":"Diabetes Metab Syndr","authors":["Huang, Ian","Lim, Michael Anthonius","Pranata, Raymond"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32334395","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.dsx.2020.04.018","keywords":["covid-19","coronavirus","diabetes mellitus","mortality","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666138494033985537,"score":434.75076},{"pmid":32305882,"pmcid":"PMC7195018","title":"Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome.","text":["Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome.","BACKGROUND: The prognostic significance of diabetes mellitus (DM) in patients with coronavirus 2019 disease (COVID-19) remains unknown. OBJECTIVES: To assess the risk of ICU admission and morality risk in diabetic COVID-19 patients. STUDY DESING: A database search was conducted to identify studies comparing diabetic COVID-19 patients hospitalized in intensive care unit (ICU) and those reporting the overall mortality of these patients published up to March 25, 2020 within MEDLINE, Scopus and Web of Science. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed in abstracting data and assessing validity. Quality assessment was performed using the Newcastle-Ottawa quality assessment scale. The main outcome was the risk of ICU admission in diabetic patients with COVID-19 infection while the second was the mortality risk in overall diabetic COVID-19 patients. Data were pooled using the Mantel-Haenszel random effects models with odds ratio (OR) as the effect measure with the related 95 % confidence interval (CI). Statistical heterogeneity between groups was measured using the Higgins I(2) statistic. RESULTS: Among 1382 patients (mean age 51.5 years, 798 males), DM resulted to be the second more frequent comorbidities. Diabetic patients resulted to have a significant increased risk of ICU admission (OR: 2.79, 95 % CI 1.85-4.22, p < 0.0001, I(2) = 46 %). In 471 patients (mean age 56.6 years, 294 males) analysed for the secondary outcome diabetic subjects resulted to be at higher mortality risk (OR 3.21, 95 % CI 1.82-5.64, p < 0.0001, I(2) = 16 %). CONCLUSIONS: Diabetic patients with COVID-19 patients are at higher risk of ICU admission and show an higher mortality risk.","J Clin Virol","Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca","Zuliani, Giovanni","32305882"],"abstract":["BACKGROUND: The prognostic significance of diabetes mellitus (DM) in patients with coronavirus 2019 disease (COVID-19) remains unknown. OBJECTIVES: To assess the risk of ICU admission and morality risk in diabetic COVID-19 patients. STUDY DESING: A database search was conducted to identify studies comparing diabetic COVID-19 patients hospitalized in intensive care unit (ICU) and those reporting the overall mortality of these patients published up to March 25, 2020 within MEDLINE, Scopus and Web of Science. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed in abstracting data and assessing validity. Quality assessment was performed using the Newcastle-Ottawa quality assessment scale. The main outcome was the risk of ICU admission in diabetic patients with COVID-19 infection while the second was the mortality risk in overall diabetic COVID-19 patients. Data were pooled using the Mantel-Haenszel random effects models with odds ratio (OR) as the effect measure with the related 95 % confidence interval (CI). Statistical heterogeneity between groups was measured using the Higgins I(2) statistic. RESULTS: Among 1382 patients (mean age 51.5 years, 798 males), DM resulted to be the second more frequent comorbidities. Diabetic patients resulted to have a significant increased risk of ICU admission (OR: 2.79, 95 % CI 1.85-4.22, p < 0.0001, I(2) = 46 %). In 471 patients (mean age 56.6 years, 294 males) analysed for the secondary outcome diabetic subjects resulted to be at higher mortality risk (OR 3.21, 95 % CI 1.82-5.64, p < 0.0001, I(2) = 16 %). CONCLUSIONS: Diabetic patients with COVID-19 patients are at higher risk of ICU admission and show an higher mortality risk."],"journal":"J Clin Virol","authors":["Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca","Zuliani, Giovanni"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305882","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jcv.2020.104354","keywords":["covid-19","diabetes","icum","ortality"],"topics":["Treatment"],"weight":1,"_version_":1666138493405888512,"score":430.43597},{"pmid":32408118,"title":"Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis.","text":["Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis.","BACKGROUND: Many studies on COVID-19 have reported diabetes to be associated with severe disease and mortality, however, the data is conflicting. The objectives of this meta-analysis were to explore the relationship between diabetes and COVID-19 mortality and severity, and to determine the prevalence of diabetes in patients with COVID-19. METHODS: We searched the PubMed for case-control studies in English, published between Jan 1 and Apr 22, 2020, that had data on diabetes in patients with COVID-19. The frequency of diabetes was compared between patients with and without the composite endpoint of mortality or severity. Random effects model was used with odds ratio as the effect size. We also determined the pooled prevalence of diabetes in patients with COVID-19. Heterogeneity and publication bias were taken care by meta-regression, sub-group analyses, and trim and fill methods. RESULTS: We included 33 studies (16,003 patients) and found diabetes to be significantly associated with mortality of COVID-19 with a pooled odds ratio of 1.90 (95% CI: 1.37-2.64; p < 0.01). Diabetes was also associated with severe COVID-19 with a pooled odds ratio of 2.75 (95% CI: 2.09-3.62; p < 0.01). The combined corrected pooled odds ratio of mortality or severity was 2.16 (95% CI: 1.74-2.68; p < 0.01). The pooled prevalence of diabetes in patients with COVID-19 was 9.8% (95% CI: 8.7%-10.9%) (after adjusting for heterogeneity). CONCLUSIONS: Diabetes in patients with COVID-19 is associated with a two-fold increase in mortality as well as severity of COVID-19, as compared to non-diabetics. Further studies on the pathogenic mechanisms and therapeutic implications need to be done.","Diabetes Metab Syndr","Kumar, Ashish","Arora, Anil","Sharma, Praveen","Anikhindi, Shrihari Anil","Bansal, Naresh","Singla, Vikas","Khare, Shivam","Srivastava, Abhishyant","32408118"],"abstract":["BACKGROUND: Many studies on COVID-19 have reported diabetes to be associated with severe disease and mortality, however, the data is conflicting. The objectives of this meta-analysis were to explore the relationship between diabetes and COVID-19 mortality and severity, and to determine the prevalence of diabetes in patients with COVID-19. METHODS: We searched the PubMed for case-control studies in English, published between Jan 1 and Apr 22, 2020, that had data on diabetes in patients with COVID-19. The frequency of diabetes was compared between patients with and without the composite endpoint of mortality or severity. Random effects model was used with odds ratio as the effect size. We also determined the pooled prevalence of diabetes in patients with COVID-19. Heterogeneity and publication bias were taken care by meta-regression, sub-group analyses, and trim and fill methods. RESULTS: We included 33 studies (16,003 patients) and found diabetes to be significantly associated with mortality of COVID-19 with a pooled odds ratio of 1.90 (95% CI: 1.37-2.64; p < 0.01). Diabetes was also associated with severe COVID-19 with a pooled odds ratio of 2.75 (95% CI: 2.09-3.62; p < 0.01). The combined corrected pooled odds ratio of mortality or severity was 2.16 (95% CI: 1.74-2.68; p < 0.01). The pooled prevalence of diabetes in patients with COVID-19 was 9.8% (95% CI: 8.7%-10.9%) (after adjusting for heterogeneity). CONCLUSIONS: Diabetes in patients with COVID-19 is associated with a two-fold increase in mortality as well as severity of COVID-19, as compared to non-diabetics. Further studies on the pathogenic mechanisms and therapeutic implications need to be done."],"journal":"Diabetes Metab Syndr","authors":["Kumar, Ashish","Arora, Anil","Sharma, Praveen","Anikhindi, Shrihari Anil","Bansal, Naresh","Singla, Vikas","Khare, Shivam","Srivastava, Abhishyant"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408118","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.dsx.2020.04.044","keywords":["2019-ncov","covid-19","coronavirus","diabetes mellitus","novel coronavirus","sars-cov-2","ncov-2019"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666802845404364800,"score":413.94528},{"pmid":32173574,"pmcid":"PMC7194638","title":"Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis.","text":["Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis.","BACKGROUND: An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients.","Int J Infect Dis","Yang, Jing","Zheng, Ya","Gou, Xi","Pu, Ke","Chen, Zhaofeng","Guo, Qinghong","Ji, Rui","Wang, Haojia","Wang, Yuping","Zhou, Yongning","32173574"],"abstract":["BACKGROUND: An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients."],"journal":"Int J Infect Dis","authors":["Yang, Jing","Zheng, Ya","Gou, Xi","Pu, Ke","Chen, Zhaofeng","Guo, Qinghong","Ji, Rui","Wang, Haojia","Wang, Yuping","Zhou, Yongning"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173574","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.ijid.2020.03.017","keywords":["covid-19","clinical characteristics","comorbidities","epidemiology","meta-analysis","sars-cov-2"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1666138492594290689,"score":367.76862},{"pmid":32232218,"pmcid":"PMC7096724","title":"Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.","text":["Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.","Introduction: In the beginning of 2020, an unexpected outbreak due to a new corona virus made the headlines all over the world. Exponential growth in the number of those affected makes this virus such a threat. The current meta-analysis aimed to estimate the prevalence of underlying disorders in hospitalized COVID-19 patients. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Web of science, and Google scholar, to find articles published until 15 February 2020. All relevant articles that reported clinical characteristics and epidemiological information of hospitalized COVID-19 patients were included in the analysis. Results: The data of 76993 patients presented in 10 articles were included in this study. According to the meta-analysis, the pooled prevalence of hypertension, cardiovascular disease, smoking history and diabetes in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%), 12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI 6.57%-9.28%), respectively. Conclusion: According to the findings of the present study, hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney disease were among the most prevalent underlying diseases among hospitalized COVID-19 patients, respectively.","Arch Acad Emerg Med","Emami, Amir","Javanmardi, Fatemeh","Pirbonyeh, Neda","Akbari, Ali","32232218"],"abstract":["Introduction: In the beginning of 2020, an unexpected outbreak due to a new corona virus made the headlines all over the world. Exponential growth in the number of those affected makes this virus such a threat. The current meta-analysis aimed to estimate the prevalence of underlying disorders in hospitalized COVID-19 patients. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Web of science, and Google scholar, to find articles published until 15 February 2020. All relevant articles that reported clinical characteristics and epidemiological information of hospitalized COVID-19 patients were included in the analysis. Results: The data of 76993 patients presented in 10 articles were included in this study. According to the meta-analysis, the pooled prevalence of hypertension, cardiovascular disease, smoking history and diabetes in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%), 12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI 6.57%-9.28%), respectively. Conclusion: According to the findings of the present study, hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney disease were among the most prevalent underlying diseases among hospitalized COVID-19 patients, respectively."],"journal":"Arch Acad Emerg Med","authors":["Emami, Amir","Javanmardi, Fatemeh","Pirbonyeh, Neda","Akbari, Ali"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232218","source":"PubMed","week":"202014|Mar 30 - Apr 05","keywords":["covid-19","comorbidity","meta-analysis","severe acute respiratory syndrome coronavirus 2"],"topics":["Diagnosis"],"weight":1,"_version_":1666138492239872001,"score":361.12683}]}